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Objectives: This study aimed to determine current practice in the management and outcome of
splanchnic vein thrombosis complicating acute pancreatitis (AP).
Methods: An audit of prospectively collected data for all patients presenting with AP was conducted.
Patients with splanchnic vein thrombosis were grouped according to vessel involvement and whether or
not systemic anticoagulation was administered.
Results: Of 127 consecutive patients admitted with AP, 20 had splanchnic venous thrombosis; in all
cases the thrombosis was associated with a severe attack of AP. Involvement of the splenic vein (SV),
portal vein (PV) and superior mesenteric vein (SMV) was observed in 14, 10 and three patients, respec-
tively. Involvement of more than one vessel was observed in six patients (SV and PV in four patients; SMV
and SV in one patient; all three veins in one patient). Thromboses were colocalized with collections in 19
patients. Only four patients received systemic anticoagulation. Resolution of thrombosis was observed in
six patients over a median of 77 days. No significant differences were observed in recanalization rates
following anticoagulation (P = 0.076). No complications associated with systemic anticoagulation
occurred. One patient developed liver failure associated with progressive PV thrombosis and one patient
died.
Conclusions: Splanchnic vein thrombosis is a relatively common observation in severe AP and is
associated with pancreatic necrosis and peripancreatic collections. Recanalization is observed in almost
a third of patients, irrespective of whether or not they receive systemic anticoagulation.
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Introduction
Splanchnic vein thrombosis is a rare complication of acute pan-
creatitis (AP).1,2 It often involves the portal vein (PV), splenic vein
(SV) and superior mesenteric vein (SMV), either in combination
or separately. Splanchnic vein thromboses per se are associated
with prothrombotic or hypercoagulable disorders, but in the
context of AP a more direct inflammatory process has been impli-
cated.3 Splanchnic vein thrombosis is often an incidental finding
on radiological imaging performed to assess the severity of an
attack of AP; however, its clinical manifestations may include signs
and symptoms that overlap with those of the pancreatitis.3,4
Although the natural history of splanchnic vein thrombosis in AP
is unclear, severe haemorrhage, bowel ischaemia, portal hyperten-
sion and liver failure have been reported.1 Based on the results of
a large, prospective, multicentre study, the European Network for
Vascular Disorders of the Liver (EN-Vie) recommended the utili-
zation of early anticoagulation in patients with acute PV throm-
bosis in non-cirrhotic, non-malignant patients.5 Furthermore, SV
thrombosis associated with ascites was found to have a poor prog-
nosis, suggesting that such patients should receive anticoagulation
and/or thrombolysis.5
Patients with severe AP are perceived to be at increased risk for
haemorrhage as a result of pseudoaneurysms, the need for
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pancreatic debridement and the frequent utilization of radiologi-
cal drainage to treat infective collections. Given the heterogeneous
study population in the recently published European study,5 and
the inherent perceived risk for early anticoagulation in patients
with severe AP, the aim of the present study was to review a
single-institution experience of the management and outcome of
patients with splanchnic vein thrombosis specifically associated
with AP.
Materials and methods
A retrospective analysis of prospectively collected clinical data for
patients diagnosed with splanchnic vein thrombosis associated
with an attack of AP was conducted. The study centre was a
tertiary referral centre at the Royal Free Hospital, London. Data
were collected for the period from January 2008 to December
2009 inclusive. The study was approved by the local research ethics
committee.
An attack of AP was defined according to clinical (acute
abdominal pain requiring hospitalization) and biochemical
(serum amylase or lipase levels exceeding three times the upper
limit of normal) criteria or radiologically by contrast-enhanced
computed tomography (CT). The severity of AP was classified in
accordance with the Atlanta Criteria.6
Venous complications were diagnosed on imaging studies
which included dynamic dual-phase, contrast-enhanced CT,mag-
netic resonance imaging (MRI) and/or colour Doppler ultra-
sonography (US).
Patients with chronic pancreatitis, knownmalignancy, cirrhosis
or established portal hypertension were specifically excluded as a
result of established prothrombotic states and the likelihood of
pre-existing splanchnic vein thrombosis.
Data pertaining to the aetiology of AP, severity, location of
thrombosis, complications associated with thrombosis (portal
hypertension, ascites, liver failure, gastric varices, gastrointestinal
haemorrhage, small bowel ischaemia), treatment and intervention
were recorded. All patients were screened for proteins C and S
deficiency, Leiden Factor V and antithrombin III.
In patients who were anticoagulated, a therapeutic dose of low
molecular weight heparin was administered when established
sepsis had been treated (1 mg/kg). Patients were subsequently
fully anticoagulated with the vitamin K antagonist, warfarin, upon
discharge [international normalized ratio (INR) 1.8–2.0].
Mortality was defined as in-hospital mortality or mortality
within 30 days of discharge. All patients were routinely followed
up in specialist outpatient clinics.
Results
A total of 127 patients with AP were admitted to the Royal Free
Hospital, London between 1 January 2008 and 31 December 2009.
Severe attacks of AP were recorded in 32 patients (25.2%), all of
whom had dynamic contrast-enhanced CT imaging at the time of
their index admission. Splanchnic vein thrombosis was detected
in 24 (18.9%) patients, of whom four were excluded because they
had a background of chronic pancreatitis with pre-existing SV
thrombosis. The remaining 20 (15.7%) patients (Table 1) were all
tertiary referrals. The aetiology of AP was gallstones in nine
patients, and alcohol-related in 11. The median age at presenta-
tion was 53.5 years (range: 36–81 years), and the sample included
nine men. Radiological findings and outcomes are shown in
Table 1. The median hospital stay was 32.5 days (range: 6–228
days).Median follow-up was 18 months (range: 15.5–36 months).
All 20 patients had a severe attack of AP. Pancreatic and/or
peripancreatic collections were present in 19 patients at the time
of transfer, although secondary infective complications developed
in eight patients. Six patients were managed with radiologically
guided drainage catheters alone, and two patients underwent pan-
creatic necrosectomy performed using a minimally invasive per-
cutaneous technique. One patient underwent a total colectomy as
a result of colonic ischaemia and closed pancreatic irrigation
without debridement. There was one death.
Pattern of splanchnic vein thrombosis
The splanchnic vessel to thrombosemost commonly was the SV in
14 patients, followed by the PV in 10 patients and the SMV in
three patients (Table 1).
Thrombosis occurred in the SV in isolation in eight patients
and in the PV in isolation in five patients. Isolated SMV throm-
bosis was observed in only one patient. The remaining patients
demonstrated a combination of SV and PV thromboses (four
patients), SMV and SV thromboses (one patient), or SV, PV and
SMV thromboses (one patient).
There was a clear association between the sites of necrosis/
peripancreatic collection and the vessels thrombosed in 16
patients (Table 2).
Overall, only four patients were anticoagulated; all of these
had PV thrombosis (three as inpatients during index admission).
Of these, in only one patient did the indication for anticoagu-
lation differ significantly from indications in those who were not
anticoagulated. In this patient the progression of the thrombosis
into the intrahepatic branches of the PV was associated with
impaired liver function (ascites). No clear indications were
observed to distinguish the other three patients who were anti-
coagulated from patients who did not receive anticoagulation
(Table 1). Hepatic decompensation occurred in only one patient,
in whom a combination of SMV, PV and SV thromboses was
seen. A patient with gallstone severe necrotizing AP was read-
mitted 14 days after discharge with ascites and mild jaundice.
Contrast-enhanced CT demonstrated thrombus propagation in
both the left and right PVs. The patient was immediately anti-
coagulated and responded well to potassium-sparing diuretics
(spironolactone).
Follow-up and outcome
Laboratory investigations for coagulation disorders were nega-
tive in all patients. Resolution of thrombosis was observed in six
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of 20 patients over a median period of 77 days (range: 10–180
days). Recanalization was observed on imaging in two patients
who did and in four patients who did not receive anticoagula-
tion (Table 2).
Of the 14 patients in whom recanalization was not observed,
three developed cavernomas demonstrated on contrast CT at
follow-up. The remaining 10 patients developed collaterals
around the SV territory. Recanalization was observed in only one
patient with SV thrombosis.
Portal vein thrombosis was observed in 10 patients, four of
whom received anticoagulation. Recanalization was observed in
two of the patients who did and two of the six patients who did
not receive anticoagulation therapy (Fisher’s exact test, P = 0.076)
(Table 2).
None of the patients had haemorrhagic complications related
to the development of portal hypertension. The single mortality in
this series occurred in a patient with gallstone pancreatitis with
complete pancreatic necrosis. An initial scan on day 5 following
admission demonstrated PV and SV thromboses. The patient
recovered from an initial transient respiratory and renal failure,
but subsequently developed left colonic ischaemia manifesting as
a perforation on day 28. A contrast CT scan confirmed the diag-
Table 1 Patient demographic data, pattern of necrosis, splanchnic vessels thrombosed and recanalization rates
Patient % necrosis Infected necrosis Vessel thrombosed Colocalized collection Anticoagulated Recanalized
1 70% DP Yes PV Yes No Yes
2 100% TP Yes SV Yes No Yes
3 70% PP No PV Yes Yes No
4 50% DP No PV, SV Yes Yes Yes
5 50% PP No PV, SV Yes No Yes
6 50% DP Yes SV Yes No No
7 100% TP No PV Yes No No
8 100% PP Yes SV Yes No No
9 50% PP No PV Yes No No
10 No necrosis No SV Yes No No
11 70% DP Yes SV Yes No No
12 No necrosis No PV Yes Yes Yes
13 No necrosis No SV No No No
14 30% PP No PV, SV Yes Yes No
15 70% PP Yes SMV Yes No Yes
16 70% PP No PV, SV, SMV No No No
17 No necrosis No SV No No No
18 70% DP Yes SV Yes No No
19 100% TP No PV, SV Yes No No
20 70% DP Yes SV, SMV No No No
DP, distal pancreas; PP, proximal pancreas; TP, total pancreas; PV, portal vein; SV, splenic vein; SMV, superior mesenteric vein.
Table 2 Pattern of splanchnic vein thrombosis and recanalization rates
Vessel thrombosed n Colocalized
collections, n




PV (all) 10 9 4 2 2
PV only 5 5 2 1 1
PV + SV 4 4 2 1 1
PV + SV + SMV 1 0 0
SV (all) 14 10 2 2 1
SV only 8 6 0 1 0
SV + SMV 1 1 0 0 0
SMV (all) 3 2 0 1 0
SMV only 1 0 0 1 0
PV, portal vein; SV, splenic vein; SMV, superior mesenteric vein.
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nosis and demonstrated near complete resolution of the PV
thrombus and persistence of SV occlusion. A total colectomy was
performed. However, the patient died from ensuing sepsis-related
multi-organ failure on day 34.
Discussion
Splanchnic vein thrombosis complicating an attack of severe AP is
uncommon and has a reported incidence of 1–2%.1 The vessel
that is by far the most commonly involved is the SV (in 70% of
patients); this involvement may be related to its very close prox-
imity to the inflamed pancreas and is supported by a clear asso-
ciation between peripancreatic inflammation and direct venous
compression by collections in 80% of patients in this series. This
result is supported by descriptions in the literature of vascular
complications as late phenomena in the course of necrotizing AP.4
This also suggests that the most appropriate way of treating and
possibly preventing splanchnic vein thrombosis in AP is probably
by intervening to drain infected peripancreatic collections in a
timely manner.
From a pathophysiological point of view, splanchnic venous
thrombosis may be linked to inherited coagulation disorders, such
as deficits of protein C or protein S,7 or acquired coagulopathies
such as antithrombin III deficiency. Intra-abdominal inflamma-
tion associated with AP itself may cause transient procoagulation
disorders.8
In this series, four patients had a severe form of PV thrombosis
with intrahepatic extension into both main branches of the PV.
These were the only patients to be anticoagulated. Six other
patients with PV thrombosis did not receive anticoagulation,
which suggests the lack of a standardized treatment in the setting
of AP. This probably reflects the reluctance of surgeons to give
therapeutic doses of heparin in the context of severe pancreatitis
with potentially infected peripancreatic collections or pancreatic
necrosis that may require urgent drainage, and the potential for
haemorrhagic complications. It should be remembered that
almost all of these patients had significant pancreatic and peri-
pancreatic collections that merited percutaneous drainage, and
two patients underwent pancreatic necrosectomy.
According to a recent Europe-wide, multicentre, prospective
study, treatment with anticoagulation is efficacious but has a
lower rate of resolution than intravascular infusion of throm-
bolytics.5 Early diagnosis and treatment with anticoagulant
therapy, heparin and vitamin K antagonists allowed recanalization
in about one third of patients, especially in recently formed
thromboses.5 The type of anticoagulation (heparin or vitamin K
antagonists) administered does not appear to influence recanali-
zation, as demonstrated in the study published by Plessier et al.5
Ascites and PV thrombosis with concomitant SV obstruction were
identified as factors predictive of worse evolution.5
Within the current study a higher rate of recanalization was
observed amongst patients who received anticoagulation. Inter-
estingly, however, the rate of recanalization observed in patients
with splanchnic vein thrombosis who did not receive anticoagu-
lation was similar to that in the anticoagulation arm of the EN-Vie
study.5 The disparity may be explained by the heterogeneity of
disorders included in the European study, in which a local risk
factor was identified in 21% of patients, and one or more pro-
thrombotic abnormalities were identified in 52% of patients. By
contrast, none of the patients in this series were found to have
procoagulation disorders, albeit that the population cohort was
comparatively smaller.
Splanchnic vein thrombosis did not resolve in 14 patients, rep-
resenting a rate of non-resolution with anticoagulant treatment
similar to that found in the literature.5,7–11 The majority of the 14
patients with splanchnic venous thrombosis that did not recana-
lize had SV thrombosis (Table 1) and, not surprisingly, 11 devel-
oped collaterals mainly around this area and three developed
porto–portal collaterals manifesting as cavernomas. None of these
patients developed portal hypertension, probably because the flow
was shunted through the collaterals and cavernomas. Patients with
cavernoma are at risk for potentially fatal intra-abdominal haem-
orrhage, recurrent thrombosis and extrahepatic biliary obstruc-
tion. Of greater interest, however, was the similar rate of
recanalization among patients with PV thrombosis, irrespective of
treatment with anticoagulants.
Mortality associated with acute SMV thrombosis in the
general population is high, at 20–50%,12,13 depending on the
grade of obstruction, the collateral vascularization, comorbidi-
ties, and delay in diagnosis and treatment. However, in the
current series SMV thrombosis did not appear in itself to be an
indication for anticoagulation therapy, and no associated com-
plications were observed. However, based on our experience and
given the limitations of the current study, we would advocate
anticoagulation if there is evidence of progression of PV throm-
bosis, ascites and/or SMV thrombosis (in view of the increased
risk for mortality).
Conclusions
Splanchnic vein thrombosis is a relatively common observation
in patients with severe AP; in the vast majority of patients it
is associated with pancreatic necrosis and peripancreatic
collections. Colocalization of peripancreatic collections and
splanchnic vein thrombosis suggests that compression and
perivascular inflammation are important mechanisms. Recanali-
zation is observed in almost a third of patients, irrespectively of
whether or not they receive systemic anticoagulation, and this
may reflect the resolution of the AP itself and/or the drainage of
adjacent collections. The role of systemic anticoagulation in
splanchnic vein thrombosis associated with AP needs to be for-
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